Changes in the Prescription of Glucose-Lowering Medications in Patients With Type 2 Diabetes Mellitus After a Cardiovascular Event: A Call to Action From the DATAFILE Study.
Adrenergic beta-Antagonists
/ therapeutic use
Aged
Angiotensin Receptor Antagonists
/ therapeutic use
Angiotensin-Converting Enzyme Inhibitors
/ therapeutic use
Cardiovascular Diseases
/ complications
Cholesterol, LDL
Diabetes Mellitus, Type 2
/ complications
Dual Anti-Platelet Therapy
Female
Glucagon-Like Peptide-1 Receptor
/ agonists
Glycated Hemoglobin
/ metabolism
Heart Failure
/ complications
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/ therapeutic use
Hypoglycemic Agents
/ therapeutic use
Italy
Male
Metformin
/ therapeutic use
Middle Aged
Myocardial Infarction
/ complications
Myocardial Ischemia
/ complications
Myocardial Revascularization
Practice Patterns, Physicians'
/ statistics & numerical data
Sodium Potassium Chloride Symporter Inhibitors
/ therapeutic use
Sodium-Glucose Transporter 2 Inhibitors
/ therapeutic use
appropriateness
diabetes mellitus
pharmacology
Journal
Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524
Informations de publication
Date de publication:
16 07 2019
16 07 2019
Historique:
entrez:
5
7
2019
pubmed:
5
7
2019
medline:
13
11
2020
Statut:
ppublish
Résumé
Background Evidence accumulated that some glucose-lowering medications protect against cardiovascular events ( CVEs ) in patients with type 2 diabetes mellitus (T2DM) and established cardiovascular disease. The present study evaluated if and how glucose-lowering medication prescription pattern changes in T2DM after a CVE. Methods and Results DATAFILE (Diabetes Therapy After a Cardiovascular Event) was a retrospective multicenter study conducted at 12 diabetes mellitus specialist outpatient clinics in Italy. We identified T2DM patients with an incident CVE for whom a follow-up visit was available after the event. We selected control T2DM patients without an incident CVE , who were matched with cases for age, sex, known diabetes mellitus duration, baseline hemoglobin A
Identifiants
pubmed: 31269877
doi: 10.1161/JAHA.119.012244
pmc: PMC6662129
doi:
Substances chimiques
Adrenergic beta-Antagonists
0
Angiotensin Receptor Antagonists
0
Angiotensin-Converting Enzyme Inhibitors
0
Cholesterol, LDL
0
Glucagon-Like Peptide-1 Receptor
0
Glycated Hemoglobin A
0
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Hypoglycemic Agents
0
Sodium Potassium Chloride Symporter Inhibitors
0
Sodium-Glucose Transporter 2 Inhibitors
0
hemoglobin A1c protein, human
0
Metformin
9100L32L2N
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e012244Références
BMJ Open. 2012 Jul 13;2(4):
pubmed: 22798258
Diabetes Care. 2018 Dec;41(12):2669-2701
pubmed: 30291106
Circ Res. 2014 May 23;114(11):1788-803
pubmed: 24855202
Lancet Diabetes Endocrinol. 2018 Feb;6(2):105-113
pubmed: 29221659
Cardiovasc Diabetol. 2015 Aug 07;14:100
pubmed: 26249018
N Engl J Med. 2015 Dec 3;373(23):2247-57
pubmed: 26630143
Circulation. 2019 Jan 15;139(3):362-365
pubmed: 30586788
Diabetes Obes Metab. 2018 Jun;20(6):1337-1341
pubmed: 29405543
Vascul Pharmacol. 2011 Jul-Sep;55(1-3):10-6
pubmed: 21664294
Clin Chem. 1990 Jan;36(1):15-9
pubmed: 2297909
N Engl J Med. 2013 Oct 3;369(14):1327-35
pubmed: 23992602
N Engl J Med. 2019 Jan 24;380(4):347-357
pubmed: 30415602
Diabet Med. 2013 Oct;30(10):1160-71
pubmed: 23663156
JAMA Intern Med. 2018 Jul 1;178(7):903-910
pubmed: 29868840
N Engl J Med. 2017 Aug 17;377(7):644-657
pubmed: 28605608
N Engl J Med. 2013 Oct 3;369(14):1317-26
pubmed: 23992601
J Am Heart Assoc. 2019 Jul 16;8(14):e012244
pubmed: 31269877
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
Diabetes Care. 2018 Mar;41(3):547-553
pubmed: 29305402
Ann Intern Med. 2017 Feb 7;166(3):225-226
pubmed: 28055052
Cardiovasc Diabetol. 2016 Aug 11;15(1):111
pubmed: 27514514
Diabetes Care. 2018 Aug;41(8):1783-1791
pubmed: 29903847
Nat Rev Endocrinol. 2012 Feb 07;8(8):495-502
pubmed: 22310849
BMJ. 2011 Mar 17;342:d1309
pubmed: 21415101
Diabetes Care. 2018 Jan;41(Suppl 1):S86-S104
pubmed: 29222380
JAMA. 2019 Jan 1;321(1):69-79
pubmed: 30418475
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
BMJ. 2009 Dec 03;339:b4731
pubmed: 19959591
N Engl J Med. 2016 Jul 28;375(4):311-22
pubmed: 27295427
Ann Intern Med. 2017 Feb 7;166(3):191-200
pubmed: 28055049
JAMA. 2007 Sep 12;298(10):1180-8
pubmed: 17848652
N Engl J Med. 2017 Sep 28;377(13):1228-1239
pubmed: 28910237
Diabetologia. 2018 Jan;61(1):58-65
pubmed: 28913543
N Engl J Med. 2015 Jul 16;373(3):232-42
pubmed: 26052984
Diabetes Care. 2018 Mar;41(3):596-603
pubmed: 29311155